The role of bromocriptine in the treatment of patients with active rheumatoid arthritis

Aim We decided to determine the effectiveness of oral bromocriptine in patients with active rheumatoid arthritis (RA) who are in methotrexate (MTX) therapy. Methods Patients receiving stable doses of MTX were randomized to one of two groups and received 3 months of double‐blind bromocriptine (5 mg/d...

Full description

Saved in:
Bibliographic Details
Published in:International journal of rheumatic diseases 2013-12, Vol.16 (6), p.662-666
Main Authors: Salesi, Mansour, Sadeghihaddadzavareh, Somayeh, Nasri, Peyman, Namdarigharaghani, Nasrin, Farajzadegan, Ziba, Hajalikhani, Mehri
Format: Article
Language:English
Subjects:
Administration, Oral
Adult
Antirheumatic Agents - administration & dosage
Antirheumatic Agents - adverse effects
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - diagnosis
Arthritis, Rheumatoid - drug therapy
bromocriptine
Bromocriptine - administration & dosage
Bromocriptine - adverse effects
Bromocriptine - therapeutic use
disease activity index
Double-Blind Method
Drug Therapy, Combination
Female
Humans
Iran
Male
Methotrexate - therapeutic use
Middle Aged
rheumatoid arthritis
Severity of Illness Index
Time Factors
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim We decided to determine the effectiveness of oral bromocriptine in patients with active rheumatoid arthritis (RA) who are in methotrexate (MTX) therapy. Methods Patients receiving stable doses of MTX were randomized to one of two groups and received 3 months of double‐blind bromocriptine (5 mg/day) or matching placebo. The moderate and major outcome measures were the proportion of patients with > 0.6 and > 1.2 improvement in RA based on the Disease Activity Score 28 (DAS28) at 3 months. Safety measures included adverse events and laboratory assessments. Results On a background treatment of MTX, the percentage of patients with moderate and major DAS28 responses at 3 months in the bromocriptine group (73.8%/59.5%) was not significantly different from placebo (63.1%/31.6%). Side effects were typically mild and included mild nausea and sleep disturbance; we did not have any adverse events resulting in discontinuation of the study drug. Conclusion In patients with active RA receiving stable doses of MTX, bromocriptine showed non‐significant improvement in efficiency outcomes compared to placebo.
ISSN:1756-1841
1756-185X
DOI:10.1111/1756-185x.12015